ESMO - Eur. Oncology is looking for an editor-in-chief for the newly journal ESMO Rare Cancers. More info at:

esmo.org/about-esmo/org…

Congrats Jordi! An important paper addressing an urgent need in clinic!

🚀 Just out in Annals of Oncology: ETOP IBCSG Partners Foundation's position statement on antibody-drug conjugates (ADC) in lung and breast cancer.
Honored to be a part of it, diving into the current evidence & future directions for clinical ADC development
annalsofoncology.org/article/S0923-…

🆕ADC landscape…from the analyst’s couch, investigating innovation in the clinical pipeline across 5 design levers: target, payload, antibody, linker & conjugation method
“A one-size fits all” technology is unlikely to emerge in the near-term!
nature.com/articles/d4157……

🛎 just published in NEJM our editorial on the groundbreaking ALINA trial, evaluating the role of adjuvant alectinib in patients with resected NSCLC carrying ALK rearrangements.
A major advance for our patients!
🔗nejm.org/doi/full/10.10…

FLAURA2: On-treatment plasma EGFRm clearance prognostic but not predictive benefit with osimertinib + ChemoT vs Osi alone by P.Jänne at #AACR24 Gustave Roussy Dana Farber's EGFR-Mutant Lung Cancer Center Dana-Farber News EGFR Resisters

Excited to see AACR launching social media ambassadors following our innovative format developed by ESMO - Eur. Oncology communication committee!
👏Collaboration at its finest. #AACR24

Looking forward to your ASCO session! #ASCO24 📖✨

👁️‍🗨️🔦Why is this PR of Bristol Myers Squibb so crucial for our community?
👇📝
During #ESMO20 , the results of CodeBreak-200 were presented, later published in The Lancet, showing a PFS improvement with sotorasib vs. docetaxel by just over a month: 5.6 vs. 4.5 months, with an HR of 0.66.…

… #ASCO24 🚨

🚀 Excited to announce our latest Cell publication on 'Cancer biomarkers: Emerging trends and clinical implications for personalized treatment.'
An important collaboration shedding light on promising avenues in cancer research.📑✨
sciencedirect.com/science/articl…

🚀 Join us in less than 1 hour for an insightful discussion on non-oncogene-addicted metastatic NSCLC in the ESMO - Eur. Oncology Guidelines real-world cases webinar. Engage with Hongcheng Zhu 祝鸿程, Solange Peters, and Bennouna Jaafar. Don't miss out! #NSCLC #ESMOGuidelines

Don't miss this essential read! 📖 Pasi Jänne & colleagues Dana-Farber delve into a crucial topic: #LungCancer in non-smokers. Published in NatureRevClinOncol, it's a must-read
#LCSM . Check it out!
nature.com/articles/s4157…

⁦ESMO - Eur. Oncology⁩ Summit Latin America was a success in São Paulo! 🇧🇷
Honoured to be there with many friends and colleagues!!
⁦Evandro de Azambuja, MD, PhD⁩ ⁦Teresa Amaral, MD, PhD⁩ ⁦Andres Cervantes⁩ linkedin.com/posts/antonio-…

Absolutely thrilled for you, Jill! 🌟
Your tireless efforts to advance research and empower patient voices are nothing short of extraordinary.
Your impact is felt far and wide.
Keep shining bright! 🌟 🤗
#ASCO24 #PatientAdvocateAward